<DOC>
	<DOCNO>NCT01836653</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety mFOLFOX6+bevacizumab mFOLFOX6+cetuximab liver metastasis KRAS Exon 2 wild type ( protocol 1.0-1.2 edition ) RAS wild type ( protocol 2.0 edition ) colorectal cancer .</brief_summary>
	<brief_title>Achievement Improved Survival Molecular Targeted Chemotherapy Liver Resection Not Optimally Resectable Colorectal Liver Metastases</brief_title>
	<detailed_description>Description : The purpose study evaluate efficacy safety mFOLFOX6+bevacizumab mFOLFOX6+cetuximab liver metastasis KRAS Exon 2 wild type ( protocol 1.0-1.2 edition ) RAS wild type ( protocol 2.0 edition ) colorectal cancer .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Histopathologically confirm colorectal cancer ( adenocarcinoma ) exclude vermiform appendix cancer proctos cancer . 2 . RAS wild type 3 . Synchronous* metachronous liver limited meitastasis extrahepatic desiease shychronous liver limited metastasis primary lesion less two third circumference patient primary lesion two third circumference enrol primary resection 4 . Patients one lesion ( ) diameter 1 cm large ( RECEST v1.1 ) able ass continuously basis protocol contrast enhance CT contrast enhance MRI liver : ( 1 ) Liver metastases 5 ( 2 ) Liver metastases 5 cm large great dimension ( 3 ) Unresectable consider remain hepatic function ( 4 ) Invasion hepatic vein inferior vena cava ( 5 ) Invasion right leave hepatic artery portal vein 5.No prior chemotherapy colorectal cancer include hepatic arterial infusion . Excluding postoperative preoperative chemoradiotherapy except rectal cancer synchronous liver metastasis . Patients receive postoperative chemotherapy contain oxaliplatin enrol 24 week last oxaliplatin administration . 6.No previous treatment include ablation therapy , cryotherapy chemotherapy metastases 7.Age enrollment &gt; =20 = &lt; 80 year 8.The Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 9.Life expectancy day enrollment 3 month longer 10.Major organ function less 14 day prior entry meet follow criterion . 1 . Neu &gt; = 1500/mm3 2 . Pt &gt; = 10.0x10^4/mm3 3 . Hb &gt; = 9.0 g/dL 4 . Tbil = &lt; 2.0 mg/dL 5 . AST ALT = &lt; 200 IU/L 6. sCr = &lt; 1.20 mg/dL 7 . INR &lt; 1.5 8 . Proteinuria = &lt; 2+ 11.Written informed consent 1 . Previously experience severe allergic reaction drug 2 . Receiving antiplatelet drug ( aspirin &gt; = 325 mg/day ) NSAIDs 3 . Receiving chronic systemic corticosteroid treatment 4 . Surgery/ biopsy skin incision traumatic injury suture le 14 day prior entry . Excluding , suture implant venous reservoir catherter allow . 5 . Severe postoperative complication ( e.g . postoperative infection , anastomic dehiscence paralytic ileus ) 6 . Diagnosed hereditary colorectal cancer 7 . Active malignancy 8 . Cerebrovascular disease symptom less 1 year prior entry 9 . Pleural effusion , ascites cardiac effusion require drainage 10 . Hemorrhage/bleeding , paralytic ileus , obstruction ulceration gastrointestinal tract 11 . Perforation gastrointestinal tract less 1 year prior entry 12 . Presence active infection 13 . HBs antigen HCV antibody positive 14 . Uncontrolled comorbidity include hypertension , diabetes , arrhythmia , disease ( cardiac disorder , interstitial pneumonia renal disorder ) 15 . Presence &gt; = grade 2 diarrhea 16 . Presence &gt; = grade 1 peripheral neuropathy 17 . Pregnant lactating woman . Women men childbearing potential unwilling use effective mean contraception 18 . Psychosis psychiatric symptom able comply protocol 19 . Any medical condition disable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Bevacizumab</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>KRAS wild type colorectal cancer</keyword>
	<keyword>RAS wild type colorectal cancer</keyword>
	<keyword>liver metastasis</keyword>
</DOC>